SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim’s Antifungal Webinar

Rhea-AI Summary

SCYNEXIS, a biotechnology firm, announced Dr. Marco Taglietti's participation in H.C. Wainwright’s 22nd Annual Global Investment Healthcare Conference from September 14-16, 2020. He will speak on September 15 at 2:30 p.m. ET. Additionally, Dr. Taglietti will join a panel at Maxim’s antifungal webinar on September 17, 2020, at 11:00 a.m. ET, discussing fungal diseases. A webcast of the HCW conference will be available on the SCYNEXIS website for 30 days post-event.

SCYNEXIS focuses on innovative therapies for difficult infections and is developing ibrexafungerp for serious fungal infections.

JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Marco Taglietti, Chief Executive Officer, will participate in a fireside chat at H.C. Wainwright’s 22^nd Annual Global Investment Healthcare Conference taking place September 14-16, 2020. Dr. Taglietti will also partake in a panel discussion at Maxim’s antifungal webinar taking place September 17, 2020.

Presentation details:

H.C. Wainwright 22nd Annual Global Investment Conference
Presentation Date:	Tuesday, September 15, 2020
Presentation Time:	2:30 p.m. ET
Webcast:	https://wsw.com/webcast/hcw7/register.aspx?conf=hcw7&page=scyx&url=https://wsw.com/webcast/hcw7/scyx
Maxim’s Antifungal Webinar
Webinar Topic:	A Too Quiet Pandemic – Fungal Disease
Date:	Thursday, September 17, 2020
Time:	11:00 a.m. ET
Register to attend via link

A webcast of the HCW presentation and a recording of the Maxim webinar will be available for 30 days on the SCYNEXIS website at: https://www.scynexis.com/news-media/events

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com

FAQ

What is SCYX participating in on September 15, 2020?

SCYX will participate in H.C. Wainwright’s 22nd Annual Global Investment Healthcare Conference on September 15, 2020, at 2:30 p.m. ET.

When is the Maxim antifungal webinar for SCYX?

The Maxim antifungal webinar featuring SCYX will take place on September 17, 2020, at 11:00 a.m. ET.

Where can I find the webcast of SCYX's presentation?

The webcast of SCYX's presentation at the H.C. Wainwright conference will be available on their website for 30 days after the event.

What is the focus of SCYNEXIS's lead product candidate, ibrexafungerp?

Ibrexafungerp is focused on treating serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species.